142P CODAK real-world study: Interim analysis of clinical outcomes in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (CRT) in the United Kingdom
| Autor: | Franks, K., Ahmed, M., Smith, D., Shaw, P.H., Banna, G., Cominos, M., Walther, J., Talbot, T., Taylor, P., Blak, B., Lindqvist, L., Paul, S.K., Vincent, D. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2022 16 Supplement 1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|